Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report

Nick Thomson, MD,1 Karel Pacak, MD, PhD, DSc,2 Meic H. Schmidt, MD, MBA,3,9 Cheryl A. Palmer, MD,4,9 Karen L. Salzman, MD,5,9 Marjan Champine, MS, CGC,6,9 Joshua D. Schiffman, MD,7,9 and Adam L. Cohen, MD, MS8,9

1Department of Internal Medicine, University of Arizona College of Medicine Phoenix, Arizona; 2Section on Medical Neuroendocrinology, National Institutes of Health, Bethesda, Maryland; Departments of 3Neurosurgery; 4Pathology, Division of Anatomic Pathology; 5Radiology, Division of Neuroradiology; 6Population Health Sciences; 7Pediatrics and Oncological Sciences; and 8Medicine, Division of Oncology, University of Utah, Salt Lake City; and 9Huntsman Cancer Institute, Salt Lake City, Utah

Leptomeningeal dissemination of paraganglioma is rare, with only 2 prior cases in the literature. The authors present the case of a metastatic low-grade lumbar paraganglioma via leptomeningeal dissemination. This report emphasizes the utility of 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA) PET scanning for diagnosis, as well as the combination of radiation therapy and alkylating chemotherapeutic agents for the treatment of this rare phenomenon. The patient was a 61-year-old woman who presented with low-back pain and was found to have an isolated L-3 intrathecal tumor on MRI. Sixteen months after gross-total en bloc resection of the paraganglioma, the patient again became symptomatic with new neurological symptoms. MRI findings revealed enhancing leptomeningeal nodules throughout the spine. 18F-FDOPA PET/CT scanning was used to confirm the diagnosis of disseminated paraganglioma. Intrathecal thiotepa, radiation therapy, and systemic therapy with capecitabine and temozolomide have been used sequentially over a 2-year period, with each able to stabilize tumor growth for several months. The authors also summarize the 2 other reports of leptomeningeal dissemination of paragangliomas in the literature and compare the course and management of the 3 cases.

https://thejns.org/doi/abs/10.3171/2016.10.SPINE16948

KEY WORDS paraganglioma; spinal neoplasm; neuroendocrine tumor; metastasis; lumbar; oncology
Operation

An L2–4 laminectomy was performed in February 2012. Notedly thin dura and arachnoid mater over the underlying tumor were opened to immediately reveal an encapsulated tumor originating from the filum. Arachnoid adhesions were carefully cauterized, after which a gross-total en bloc resection of the extramedullary mass was performed without violating its capsule. Following the surgery, the patient experienced complete resolution of her low-back pain, but she did note residual rectal numbness and weakness without loss of bowel or bladder function.

Pathological Examination

Neuropathological examination demonstrated a thinly encapsulated, pink-tan to maroon tumor that was 4.6 × 2.0 × 1.8 cm in size. The tumor came within 0.6 cm of the nearest margin without evidence of dural sac invasion. It was estimated that complete macroscopic surgical removal was attained. With H & E staining, the tumor contained relatively uniform, round-to-oval neoplastic cells arranged in nests (the classically described “Zellballen” pattern). Focal pseudorosetting patterns were seen. The nuclei were centrally located and displayed “salt and pepper”-type chromatin. Moderate amounts of granular cytoplasm were present (Fig. 1). The tumor nests were surrounded by delicate monolayers of thin, elongated sustentacular cells. Fragments of bone were included in the tumor matrix. Immunohistochemical staining performed on the tumor revealed it to be positive for nonspecific enolase and synaptophysin (Fig. 2), both stains of neuroendocrine origin, and negative for glial fibrillary acidic protein and epithelial membrane antigen. The histopathology was diagnostic of a paraganglioma.

Molecular Genetics

Germline genetic testing revealed no clinically significant alteration in the SDHB, SDHC, or SDHD genes; however, a variant of unknown clinical significance, p.H50R or c.149A>G, in exon 2 of the SDHD gene was identified.
It is not currently confirmed to be deleterious or causative of classic hereditary paraganglioma syndrome, and it is known to exist in the general population of healthy individuals with a frequency of approximately 3%. Site-specific genetic testing for this alteration was offered to the patient’s parents to clarify whether it may have been associated with her paraganglioma; however, this offer was declined. Plasma metanephrines were measured to be within normal limits (< 0.10 nmol/L), as were urine and serum normetanephrine (0.81 nmol/L in both samples).

Postoperative Course

Follow-up MRI at 6 months revealed no residual tumor. In June 2013, the patient developed acute-onset, severe low-back pain radiating down her right thigh and new-onset numbness of her right buttck. MRI revealed multiple, extensive leptomeningeal foci along the conus medullaris and nerve roots, spreading upward to the level of T-1 (Fig. 3), with no evidence of metastatic disease in the cervical spine or brain. Three separate lumbar punctures were performed with cytologies negative for malignancy. Given the location and size of the recurrent disease, biopsy was not feasible to confirm diagnosis.

3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (18F-FDOPA) is known to accumulate within neuroendocrine tumors. By synthetically attaching a radiotracer fluorine-18 isotope to the FDOPA molecule and allowing cellular uptake via the neutral amino acid transporter (LAT1/4F2hc), a PET/CT can then be used for precise localization of tumors.20 68Ga-DOTATATE (68Ga–tetraazacyclododecane tetraacetic acid–octreotate) PET/CT may also be used for the detection of recurrent or metastatic paragangliomas.11,12 Our patient was referred to the National Institutes of Health, where findings on an 18F-FDOPA PET/CT were positive for recurrent paraganglioma in the same distribution as the MRI findings (Fig. 4). Also tested at the National Institutes of Health were plasma chromogranin A, catecholamine, and metanephrine levels that were found to be within normal limits.

Due to concurrent unstable cardiac and pulmonary comorbidities, the patient was observed initially until her other conditions were treated. Once her cardiac and pulmonary conditions resolved, her back pain and numbness returned to the baseline levels she had had since her initial surgery. Because the extent of disease precluded curative treatment and her symptoms were at baseline, she was observed for a total of 9 months until March 2014, when she developed new-onset numbness of her lower extremities and accompanying worsening MRI findings. An Ommaya reservoir was placed for intrathecal delivery of thiotepa, which was given twice weekly for 6 weeks, followed by weekly treatments for 8 weeks. In August 2014, she developed progressive neurological symptoms in the S-1 distribution, similar to those that she previously experienced. MRI confirmed progression of her disease in the sacral spine, with multiple foci involving nerve roots of the cauda equina. The patient then received radiation therapy at the level of T-12 through the sacral spinal canal (45 Gy) with L2–sacral canal boost (50 Gy) from September to October 2014, which improved her neurological symptoms.

Because the patient’s thoracic spine metastases had been stable on the intrathecal thiotepa, the sacral progression was thought to be due to poor penetration of the drug into the bulky sacral recurrence. Therefore, after the lumbosacral radiation therapy, intrathecal thiotepa was resumed, and serial MR images revealed stable disease. Intrathecal thiotepa was continued monthly until August 2015, when MRI revealed continued dissemination super-
Parietal and cerebellar lesions where a 3-mm enhancing lesion was seen on the left side. Treatment was then changed to capecitabine and temozolomide, and repeat MRI through May 2016 revealed stable disease.

**Discussion**

Paragangliomas are mostly benign but do have significant recurrence rates that differ with site of disease and can recur decades after resection. Some studies have indicated metastasis rates of 28% to 42% for retroperitoneal paragangliomas. Carotid body tumors have been found to have the lowest metastatic rates (2%–9%). Local recurrence after surgical excision is more common in patients with a genetic predilection compared with sporadic paragangliomas. Because of the few instances where dissemination of recurrent, macroscopically resected tumor has occurred, treatment must be determined on an individual basis.

Several targeted therapies are being developed for the treatment of metastatic paragangliomas. Peptide receptor radionuclide therapy has been shown to be effective in treating other neuroendocrine tumors and is possibly effective in the treatment of metastatic paragangliomas. However, somatostatin analogs used in peptide receptor radionuclide therapy do not cross the blood-brain barrier and are thus ineffective for the treatment of CNS disease. Paraganglioma cell-surface ATP (adenosine triphosphate) synthase has been demonstrated as another potential therapeutic target. Resveratrol, as well as other ATP synthase targets, has been shown to potentially cross the blood-brain barrier. Further development and study of these and other novel systemic and localized treatment modalities is necessary for the advancement of treating metastatic paragangliomas.

For paragangliomas located below the neck, radiation therapy is typically used only for painful bony lesions or tumors with rapid growth. Although paragangliomas were once thought to be resistant to radiation, our case and those of others have demonstrated that radiation therapy can effectively palliate symptoms and stop growth of paraganglioma.

A review of the literature was performed to identify all reported cases of leptomeningeal dissemination of paraganglioma. A comparison of our case with that of 2 similar cases from Switzerland and Sweden reveals many similarities (Table 1). In all 3 circumstances, the paragangliomas were initially small and encapsulated and were located in the lumbosacral area, making total resection plausible. Given the anatomical locations of these lesions, local recurrence and dissemination likely occurred via the spinal subarachnoid space rather than the cerebrospinal fluid. In all 3 instances, metastatic disease was found within the cerebellum. In 2 cases, radiation therapy was successful at controlling progressive metastases. Our case also highlights that alkylating agents that penetrate the CNS can produce disease stability in leptomeningeal paraganglioma.

These cases demonstrate that although maximal safe resection is important, en bloc total resection may not prevent local dissemination through the meninges. They also illustrate that radiation therapy and alkylating agents, given either intrathecally or systemically, are active against paraganglioma. In all 3 cases, histological or genetic characteristics were initially indistinguishable from other benign paragangliomas, giving no hint of their later leptomeningeal spread.

Identification of new biomarkers to assess the aggressiveness of these tumors is needed to identify those patients who may benefit from adjuvant therapy. A high Ki-67 index has been proposed as a potential prognostic factor. A recent study evaluated 3'-deoxy-3'18F-fluorothymidine (18F-FLT) PET/CT, a PET proliferation tracer, as a potential radioimaging agent in a series of paraganglioma

**TABLE 1. A comparison of 3 cases of metastatic paragangliomas**

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Location of Primary</th>
<th>Time to Dissemination</th>
<th>En Bloc Resection</th>
<th>Sites of Dissemination</th>
<th>Treatment of Recurrence</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present study</td>
<td>Intrathecal at L-3</td>
<td>6 mos</td>
<td>Yes</td>
<td>Conus medullaris, cauda equina nerve root, thoracic spine, cerebellum</td>
<td>XRT, intrathecal thiopeta, &amp; CAPTEM</td>
<td>Alive as of August 2016 (&gt;5.5 yrs after diagnosis)</td>
</tr>
<tr>
<td>Strommer et al., 1995</td>
<td>Intradural at L-3</td>
<td>22 yrs</td>
<td>Yes</td>
<td>Multiple posterior fossa metastases: cerebellar declive, culmen &amp; rt floculus, lt inferior colliculus, as well as recurrence at original site, &amp; in the cauda equina at L4–S1</td>
<td>Median suboccipital craniotomy at which time cystic midline cerebellar lesion &amp; tumor were removed but other lesions were left behind; later (1993), hemilaminectomy of L4–5 &amp; S-1 w/ gross-total resection</td>
<td>Alive as of 1994 when manuscript was submitted</td>
</tr>
<tr>
<td>Roche et al., 1996</td>
<td>Intraspinal from L-4 to S-1</td>
<td>3 yrs</td>
<td>No</td>
<td>Conus medullaris, rt CPA, cerebellar culmen, thoracic spinal cord, conus</td>
<td>Gross-total removal of CPA tumor; however, small subarachnoid lesions were identified but not resected; XRT to the craniospinal drop neoplasms</td>
<td>4.5 years after initial surgery (6 mos after CPA recurrence, patient had fluid &amp; electrolyte imbalance following surgical intervention of small bowel obstruction &amp; died)</td>
</tr>
</tbody>
</table>

**CAPTEM = capecitabine and temozolomide; CPA = cerebellopontine angle; XRT = radiation therapy.**
patients with varying genetic backgrounds to compare 18F-FLT uptake with 18F-FDG PET/CT and evaluate classic factors of aggressiveness. There was no superiority of 18F-FLT uptake in progressive lesions, suggesting the possibility that proliferation may not be a major indicator of aggressiveness. Genetic biomarkers are also being developed as prognostic indicators. A recent study demonstrated that 53% of patients with at least 1 extra-adrenal paraganglioma had an identified germline mutation. The most commonly mutated susceptibility gene associated with pheochromocytomas and paragangliomas is succinate dehydrogenase subunit B (SDHB), which also carries the highest risk of malignancy. In patients with SDHB mutations, primary tumor size has been found to be an age-independent predictor of patient survival and metastasis. To achieve the best possible clinical outcome, patients discovered to have any SDH mutation are recommended to undergo genetic counseling and early and regular evaluations for the development of pheochromocytomas/paraganglioma.

To date, there are no large studies describing specific outcomes of metastatic paragangliomas initially located below the neck. This is, in part, due to the indolent, insidious nature of the disease, even in the setting of dissemination. In addition, the optimal therapeutic strategy for disseminated low-grade paragangliomas has yet to be defined. From our experience, we believe that alkylation chemotherapeutic agents and radiation therapy are both active modalities. It is possible that gene-targeted radiotherapeutics and other novel targeting moieties will be used in the future. Further studies are warranted to assess treatment outcomes in patients with this uncharacteristic modality of disease metastasis, with comparison of current treatment protocols and newly developed models as they become available. We also wish to emphasize the important utility of 18F-FDOPA scans in the diagnosis of unresectable, small-sized disease where biopsy is not feasible. Documentation of atypical cases such as this one is central to clinician awareness in addition to the promotion of developing novel biomarkers for malignant potential and original treatment protocols.

References


**Disclosures**

Dr. Schmidt reports that he is a consultant for Ulrich Medical USA.

**Author Contributions**

Conception and design: Thomson, Cohen. Acquisition of data: Thomson, Pacak, Schmidt, Palmer, Salzman, Champine, Cohen. Analysis and interpretation of data: all authors. Drafting the article: Thomson. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Thomson. Study supervision: Cohen.

**Supplemental Information**

**Current Affiliations**

Dr. Schmidt: New York Medical College, Westchester Medical Center & Health Network, Valhalla, New York.

**Correspondence**

Nick Thomson, Department of Internal Medicine, University of Arizona College of Medicine Phoenix, 1111 E McDowell Rd., Phoenix, AZ 85006. email: thomson6@email.arizona.edu.